奈达铂联合放疗同步治疗中晚期食管癌的临床有效性

Clinical Efficacy of Nedaplatin Combined with Radiotherapy in the Treat⁃ment of Advanced Esophageal Cancer

目的 探讨中晚期食管癌实施奈达铂联合放疗同步治疗的临床效果。方法 非随机选取2021年1月—2024年3月常熟市第一人民医院肿瘤科收治的60例中晚期食管癌患者作为研究对象,按治疗方法不同分为放疗组和同步组,各30例。放疗组行单纯放疗,同步组增加奈达铂治疗。对比两组临床疗效、肿瘤标志物、不良反应、远期生存情况。结果 同步组缓解率为73.33%(22/30)、控制率为93.33%(28/30),均高于放疗组的46.67%(14/30),73.33%(22/30),差异有统计学意义(χ^(2)=4.444、4.320,P均<0.05)。同步组的各项肿瘤标志物水平均低于放疗组,差异有统计学意义(P均<0.05)。同步组白细胞减少率为56.67%(17/30),高于放疗组的26.67%(8/30),差异有统计学意义(χ^(2)=5.554,P<0.05)。同步组的一年生存率、两年生存率均高于放疗组,差异有统计学意义(P均<0.05)。结论 奈达铂联合放疗的方案对中晚期食管癌患者而言,不仅能提高控制率和远期生存率,而且能抑制肿瘤标志物的表达,安全性高。

Objective To investigate the clinical effect of nedaplatin combined with radiotherapy in the treatment of advanced esophageal cancer.Methods From January 2021 to March 2024,sixty patients with advanced esophageal cancer admitted to the Oncology Department of Changshu First People's Hospital were non-randomly selected as the research objects.According to different treatment methods,they were divided into radiotherapy group and synchronous group,with thirty cases in each group.The radiotherapy group was treated with radiotherapy alone,and the concurrent group was treated with nedaplatin.The clinical efficacy,tumor markers,adverse reactions and long-term survival of the two groups were compared.Results The remission rate was 73.33%(22/30)and the control rate was 93.33%(28/30)in the concurrent group,which were higher than 46.67%(14/30)and 73.33%(22/30)in the radiotherapy group,and the differences were statistically significant(χ^(2)=4.444,4.320,both P<0.05).The three tumor markers in the syn-chronous group were lower than those in the radiotherapy group,the differences were statistically significant(all P<0.05).The leukopenia rate in the concurrent group was 56.67%(17/30),which was lower than 26.67%(8/30)in the ra-diotherapy group,and the difference was statistically significant(χ^(2)=5.554,P<0.05).The 1-year survival rate and 2-year survival rate of the synchronous group were higher than those of the radiotherapy group,and the differences were statistically significant(both P<0.05).Conclusion Nedaplatin combined with radiotherapy can not only improve the control rate and long-term survival rate of patients with advanced esophageal cancer,but also inhibit the expression of tumor markers with high safety.